Status:
COMPLETED
Study Of SU011248 In Patients With Metastatic Non-Small Cell Lung Cancer
Lead Sponsor:
Pfizer
Conditions:
Carcinoma, Non-Small-Cell Lung
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to test whether SU011248 has activity and is safe in patients with metastatic non-small cell lung cancer (NSCLC) who have failed a platinum-containing regimen and docetaxe...
Eligibility Criteria
Inclusion
- Histologically confirmed advanced or metastatic Non-Small Cell Lung Cancer that cannot be cured with surgery, radiation, or combination thereof
- No more than 2 prior chemotherapy treatments including treatment with a platinum containing therapy
- Evidence of measurable disease by radiographic technique
- Male or Female, 18 years or older
- ECOG performance status of 0 or 1
- Resolution of all acute toxicities of prior therapies
- Adequate organ function
Exclusion
- Major surgery or radiation therapy within 4 weeks
- Severe hemorrhage within 4 weeks
- Previous treatment with anti-angiogenesis agents
- Diagnosis of second malignancy within last five 5 years
- History of or known brain metastases, spinal cord compression, or carcinomatous meningitis
- Known HIV
- Serious acute or chronic illness
- Current treatment on another clinical trial
- Pregnant or breastfeeding
Key Trial Info
Start Date :
January 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2007
Estimated Enrollment :
111 Patients enrolled
Trial Details
Trial ID
NCT00092001
Start Date
January 1 2005
End Date
March 1 2007
Last Update
October 16 2008
Active Locations (14)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Baltimore, Maryland, United States, 21231-1000
2
Pfizer Investigational Site
City of Saint Peters, Missouri, United States, 63376
3
Pfizer Investigational Site
St Louis, Missouri, United States, 63110-1094
4
Pfizer Investigational Site
St Louis, Missouri, United States, 63110